Skip to content

Photodynamic Therapy in Anal Fistula

Efficacy of Photodynamic Therapy and Intra-lesional 5-wing in Complex Perianal Fistula

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03864718
Enrollment
49
Registered
2019-03-06
Start date
2016-01-31
Completion date
2018-12-31
Last updated
2019-03-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rectal Fistula

Brief summary

Objective: Validate and analyze the results of intralesional photodynamic therapy in the treatment of complex anal fistula. Methods: Prospective observational study including patients treated for complex anal fistula who underwent intralesional photodynamic therapy (i-PDT). Patients were included with a minimum follow up of 1-year, in order to evaluate recurrence, continence and postoperative morbidity. Intralesional 5-aminolevulinic acid gel 2% was directly injected into the fistula. The internal and external orifices were closed. After an incubation period of 2 h, the fistula was irradiated using an optical fibre connected to a red laser (MULTIDIODE 630 PDT, INTERmedic, Spain) operating at 1 W/ cm for 3 min (180 Joules).

Interventions

PROCEDUREphotodynamic therapy

Intralesional 5-aminolevulinic acid gel 2% was directly injected into the fistula. The internal and external orifices were closed. After an incubation period of 2 h, the fistula was irradiated using an optical fibre connected to a red laser (MULTIDIODE 630 PDT, INTERmedic, Spain) operating at 1 W/ cm for 3 min (180 Joules).

Sponsors

Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* complex anal fistula according to Parks classification

Exclusion criteria

* Non cryptoglandular fistulas * acute sepsis * inflammatory bowel diseases * simple fistulas (defined as subcutaneous, intersphincteric and low transsphincteric fistula) * pregnant patients * ASA IV * patients \<18 * immunocompromised * patients who refused consent.

Design outcomes

Primary

MeasureTime frameDescription
Healing12 months after surgeryYes/Not

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026